Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 diabetes mellitus. OH As are only recommended after the introduction of diet and exercise therapy for several months, because life-style modification generally improves glucose control effectively. Sulfonylureas are often prescribed for individuals with fasting hyperglycemia and insulin-deficiency, whereas biguanides or thiazolidinediones are often used among insulin-resistant diabetic patients. α-Glucosidase inhibitors or fast-acting insulin secreting drugs are suitable for patients with post-prandial hyperglycemia. OHA treatment target is to maintain a HbAlc level below 6.5% without hypoglycemia. Combination of two or more OH As is often ef...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
Little is known about the relationships between patient factors and the antihyperglycemic agents tha...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Oral hypoglycemic drugs now available are of two types. The biguanides, of which phenformin (DBI) is...
Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a hete...
peer reviewedType 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NID...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
Various new oral hypoglycaemic agents have been developed recently and have changed the therapy of t...
Hyperglycemia, or a state of high blood sugar, is a symptom of diabetes mellitus (D.M.), a complicat...
Diabetes mellitus (DM) is a major medical and social problem almost in all countries of the world. C...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
Little is known about the relationships between patient factors and the antihyperglycemic agents tha...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Various kinds of oral hypoglycemic agents (OHA) are currently available for the treatment of type 2 ...
Oral hypoglycemic drugs now available are of two types. The biguanides, of which phenformin (DBI) is...
Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a hete...
peer reviewedType 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NID...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...
Various new oral hypoglycaemic agents have been developed recently and have changed the therapy of t...
Hyperglycemia, or a state of high blood sugar, is a symptom of diabetes mellitus (D.M.), a complicat...
Diabetes mellitus (DM) is a major medical and social problem almost in all countries of the world. C...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
Till the turn of the century, treatment of hyperglycemia in Type 2 diabetes was limited to two main ...
Little is known about the relationships between patient factors and the antihyperglycemic agents tha...
The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyper...